Which EGPA patients are most likely to benefit from treatment with anti-IL-5 agents such as mepolizumab?

This is a question that is an important area of current investigation in vasculitis. In my view, patients who have primarily pulmonary and sinonasal symptoms (e.g., asthma, rhinosinusitis) are most likely to benefit from mepolizumab, given current knowledge.

It is unknown to what degree mepolizumab a...